Presentation is loading. Please wait.

Presentation is loading. Please wait.

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Published byΖηναις Αλεξίου Modified over 5 years ago

Similar presentations

Presentation on theme: "Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online."— Presentation transcript:

1 Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I
John J.P. Kastelein, et al. N Engl J Med 2007;356: online

2 Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part II
John J.P. Kastelein, et al. N Engl J Med 2007;356: online

3 Changes in Levels of High-Density Lipoprotein (HDL) and Low-Density Lipoprotein (LDL) Cholesterol in Patients Receiving Atorvastatin Alone or Atorvastatin plus Torcetrapib John J.P. Kastelein, et al. N Engl J Med 2007;356: online

4 Changes in Lipoprotein Subclasses*
John J.P. Kastelein, et al. N Engl J Med 2007;356: online

5 Baseline, Follow-up, and Change from Baseline in End Points for Maximum Carotid Intima-Media Thickness* John J.P. Kastelein, et al. N Engl J Med 2007;356: online

6 Average Maximum Carotid Intima-Media Thickness during 24 Months of Treatment
John J.P. Kastelein, et al. N Engl J Med 2007;356: online

Download ppt "Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online."

Similar presentations

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.
Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weng TC, et al. J Clin Pharm Ther 2010;35:
Slide Source: www.lipidsonline.org Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Enrollment and Outcomes J.J.P. Kastelein, et al. N Engl J Med 2008;358:1431.

Enrollment and Outcomes J.J.P. Kastelein, et al. N Engl J Med 2008;358:1431.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:1556-1563.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟８階 カンファレンス室.

Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟８階 カンファレンス室.
Solomon Tesfaye et al N Engl J Med 2005;352:341- 50 Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Kastelein JJ, et al. Circulation 2008;117:3002-9 On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.

Kastelein JJ, et al. Circulation 2008;117: On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368: 919-28.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353: 2121-34.

Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:
From: High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events: MESA (Multi-Ethnic Study of Atherosclerosis)

From: High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events: MESA (Multi-Ethnic Study of Atherosclerosis)
Baseline Characteristics of the Patients Part I

Baseline Characteristics of the Patients Part I
Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110: 3512-3517.

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Similar presentations

Ads by Google